Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
500
Millions of yenWording
Conditional
How definitive the wording is.Contents of this document
Financial Results PresentationSecond quarter (interim period) of the fiscal year ending July 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales32,441 Millions of yen+8.7%
Operating profit-2,361 Millions of yen
Ordinary income-2,437 Millions of yen
Net income-1,824 Millions of yen
Full-year earnings forecast
Net Sales
67,000 Millions of yen
Operating profit
2,000 Millions of yen
Ordinary income
2,000 Millions of yen
Profit attributable to owners of the parent
1,500 Millions of yen
Earnings per share
¥51.64
Dividend per share
¥25
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
As initially planned, upfront investments were made with the first half designated as a period of proactive investment and the second half as a period of returning to profitability.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating profit
Gross profit2,010
Advertising expenses-4,018
Research and development costs-53
Other SG&A expenses-923
New initiatives
- Redefinition of the New Value Creation 1K Project
- Expansion of loyal customers and strengthening of CRM, centered on the ニューモ product series and other products
- Strengthening the drug discovery platform through collaboration with Tohoku University and The University of Tokyo
- Drug discovery research on CADASIL with the National Cerebral and Cardiovascular Center
- Development of new electrode materials derived from eggshell membranes
- Launch of domestic supply of raw ovoveil material derived from eggshell membranes
- Commercialization of biostimulants through a Ministry of Agriculture, Forestry and Fisheries project
- Construction of a new plant by 明治薬品
Key KPIsA metric the company considers important as a management benchmark.
- Number of subscription customers758,528 EngagementsYear on year against the same period last year-4.8%
- Revenue / subscription customer¥37,876 per orderYear on year against the same period last year+16.3%
- Cumulative units sold (Tamago Samin)838 10,000 bags
- Improvement in brown rice yieldsKyoto +10%, Kumamoto +12%, Toyama +4%
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Number of subscription customers
758,528 Engagements-4.8%
Revenue / subscription customer
¥37,876 per order+16.3%
Segment results
B2B Business
Net Sales
3,576 Millions of yen-4.9%
Operating profit
502 Millions of yen
B2C Business
Net Sales
28,730 Millions of yen+10.7%
Operating profit
-1,557 Millions of yen
Biomedical business
Net Sales
104 Millions of yen
Operating profit
-260 Millions of yen
Other
Net Sales
30 Millions of yen
Operating profit
-11 Millions of yen
Medium-term management plan targets
Net Sales
1,000 Hundreds of millions of yen
Annual Dividend
Annual dividend per share¥25
Payout ratio
Rate48.4 %
Total payout ratio20 %
Unit for total shareholder return ratio%
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | Second quarter (interim period) of the fiscal year ending July 2026 |
| Net Sales | 32,441 Millions of yen (YoY +8.7%) |
| Operating profit | -2,361 Millions of yen |
| Ordinary income | -2,437 Millions of yen |
| Net income | -1,824 Millions of yen |
| Full-year earnings forecast | Net Sales 67,000 Millions of yen / Operating profit 2,000 Millions of yen / Ordinary income 2,000 Millions of yen / Profit attributable to owners of the parent 1,500 Millions of yen / Earnings per share ¥51.64 / Dividend per share ¥25 |
| Self-assessment against the plan | As initially planned, upfront investments were made with the first half designated as a period of proactive investment and the second half as a period of returning to profitability. |
| Segment results | B2B Business Net Sales 3,576 Millions of yen (YoY -4.9%) / Operating profit 502 Millions of yen / B2C Business Net Sales 28,730 Millions of yen (YoY +10.7%) / Operating profit -1,557 Millions of yen / Biomedical business Net Sales 104 Millions of yen / Operating profit -260 Millions of yen / Other Net Sales 30 Millions of yen / Operating profit -11 Millions of yen |
| Breakdown of Factors Affecting the Change | Operating profit Gross profit 2,010 / Advertising expenses -4,018 / Research and development costs -53 / Other SG&A expenses -923 |
| Key KPIs | Indicator name Number of subscription customers / Value 758,528 Engagements / Year on year against the same period last year -4.8 Engagements, Indicator name Revenue / subscription customer / Value ¥37,876 per order / Year on year against the same period last year ¥16.3 per order, Indicator name Cumulative units sold (Tamago Samin) / Value 838 10,000 bags / Year on year against the same period last year Not disclosed, Indicator name Improvement in brown rice yields / Value Kyoto +10%, Kumamoto +12%, Toyama +4% / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Number of subscription customers 758,528 Engagements (YoY -4.8%) / Revenue / subscription customer ¥37,876 per order (YoY +16.3%) |
| Medium-term management plan targets | Net Sales 1,000 Hundreds of millions of yen / Target fiscal year Not disclosed |
| Annual Dividend | Annual dividend per share ¥25 / Interim and Year-End Breakdown Not disclosed |
| Payout ratio | Rate 48.4 % / Total payout ratio 20 % / Unit for total shareholder return ratio % |
| New initiatives | Redefinition of the New Value Creation 1K Project, Expansion of loyal customers and strengthening of CRM, centered on the ニューモ product series and other products, Strengthening the drug discovery platform through collaboration with Tohoku University and The University of Tokyo, Drug discovery research on CADASIL with the National Cerebral and Cardiovascular Center, Development of new electrode materials derived from eggshell membranes, Launch of domestic supply of raw ovoveil material derived from eggshell membranes, Commercialization of biostimulants through a Ministry of Agriculture, Forestry and Fisheries project, Construction of a new plant by 明治薬品 |
Items this document does not state (15)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Upfront investments were made in line with the original plan, which designated the first half as a period of proactive investment and the second half as a period of returning to profitability. The upward revision to the full-year forecasts reflects improved profitability, primarily for the core ニューモ product series.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.